Recent Updates
Recently added Catalysts
NMRA Negative Sentiment Score: 20/100

Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion

Key Takeaway: Neumora Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the efficacy of its therapeutic candidate, Navacaprant. The lawsuit claims that the company altered clinical trial parameters and lacked adequate data in its studies. Investors are urged to file a lead plaintiff motion by April 7, 2025, to recover losses incurred during the class period. The Portnoy Law Firm is facilitating this process, offering complimentary case evaluations to affected investors.

Market Sentiment Analysis

CONCERNS & RISKS

  • Investors face a potential loss due to misleading statements from Neumora.
  • Allegations suggest the company altered clinical trial criteria to support its drug's effectiveness.
  • Phase Two trials reportedly lacked sufficient data, impacting outcome predictability.

Full Press Release Details

LOS ANGELES, March 25, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ: NMRA) investors of a class action representing investors who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commencing on or about September 15, 2023. Neumora investors have until April 7, 2025 to file a lead plaintiff motion.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The complaint alleges that during the class period, Defendants made materially false or misleading statements and failed to disclose key information. Specifically, Neumora altered BlackThorn’s original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) in an effort to justify proceeding with its Phase Three Program and demonstrate that Navacaprant, its flagship therapeutic candidate, provided statistically significant improvement in treating MDD. Additionally, the company modified the Phase Two statistical analysis plan by introducing a prespecified analysis focused on patients with moderate to severe MDD. Furthermore, the Phase Two trials lacked sufficient data—particularly regarding patient population size and the male-to-female ratio—making it difficult to accurately predict the outcomes of the KOASTAL-1 study.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising

Tags

Frequently Asked Questions

What is the deadline for Neumora investors to act?

Neumora investors must file a lead plaintiff motion by April 7, 2025.

Who should investors contact for legal advice?

Investors can contact attorney Lesley F. Portnoy at 310-692-8883 or via email.

What does the class action lawsuit allege?

The lawsuit claims Neumora provided misleading statements and failed to disclose critical information.

What was modified in Neumora’s trial criteria?

Neumora revised inclusion criteria to justify the Phase Three Program focusing on MDD.

How can investors evaluate their legal options?

The Portnoy Law Firm offers complimentary case evaluations for affected investors.

Last updated: Mar 25, 2025